ILMN vs. SMMT: Illumina vs. Summit Therapeutics Stock Comparison

Company Profile

Illumina (ILMN) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while SMMT is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Illumina (ILMN) has a non-negative beta of 1.46.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

Illumina (ILMN) at 19.72% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

Illumina (ILMN) at 20.02% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Illumina (ILMN) reports revenue growth of -0.66%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Neither Illumina (ILMN) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Illumina (ILMN) at 2.63 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Illumina (ILMN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Illumina (ILMN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Illumina (ILMN), whose P/S ratio of 7.10 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Summit Therapeutics (SMMT) at 23.13 prices even higher, above its industry range.

Valuation Metrics